BioCentury on BioBusiness,
Politics and Policy
Inside the Senate bill
Monday, August 15, 1994
The Biotechnology Industry Organization has examined the 1,400-page health care reform bill sponsored by Senate Majority Leader George Mitchell, D-Maine, and identified the provisions it believes would "adversely affect research" by the biotechnology industry. Following is the list, along with the BIO's arguments about the issues.
Rebates on prescription drugs covered under Medicare Part B
Would move drugs now covered under Part B(administered "incident" to a physician's service) into the new Medicare prescription drug benefit, which would require rebates
Biotech drugs disproportionately affected because they are administered in large part through transfusion or injection "incident" to a physician's service.
Creates additional tax for biotech drugs already on market.
Creates incentives, particularly for chemotherapies, to admit patients into hospitals.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]